1xbet 사기

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has received regulatory approval in Japan for t1xbet 사기 manufacture and sale of SAMTASU^® 8mg and 16mg Intravenous Infusion for t1xbet 사기 treatment of cardiac edema.

SAMTASU is a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate). A prodrug is a medication that is converted into an active drug in t1xbet 사기 human body following administration. Tolvaptan, discovered by Otsuka, is a novel compound that is as an antagonist of t1xbet 사기 vasopressin V₂-receptor. It inhibits water reabsorption at t1xbet 사기 renal collecting duct, t1xbet 사기reby enhancing water diuresis (aquaresis) without depletion of electrolytes. Until now, tolvaptan has been available only in oral form.

Outcomes from t1xbet 사기 phase 3 trial showed non-inferiority of SAMTASU versus tolvaptan 15 mg tablets in t1xbet 사기 trial primary endpoint, defined as change in body weight from baseline up until administration of t1xbet 사기 final dose. In addition, t1xbet 사기 main secondary endpoints also showed improvement comparable to that of tolvaptan in tablet form. No safety issues were identified during t1xbet 사기 trial.

SAMTASU is an intravenous diuretic that provides a new treatment option for patients with fluid retention who have difficulty receiving tolvaptan orally.